DXCM vs MDT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DXCM and MDT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DXCM and MDT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

DexCom is a medical-device company that pioneered continuous glucose monitoring. Its wearable sensors and transmitters measure glucose levels continuously and send readings to a phone or receiver, replacing or supplementing traditional fingerstick tests for people with diabetes. Its flagship G7 platform serves people with type 1 and type 2 diabetes, while Stelo, an over-the-counter CGM cleared for people who do not use insulin, extends the technology toward a broader wellness and metabolic-health audience. DexCom earns most of its revenue from recurring sensor sales, since users replace sensors regularly, which gives the business a razor-and-blade-like recurring quality once a patient is on the platform.

Full DXCM guide

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.

Full MDT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DXCM drivers: Expansion beyond insulin users; New products and features.
• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. For MDT, medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences.

Pick DXCM if you believe its drivers more; MDT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DXCM and MDT guides.

DXCM. Figures are approximate and tied to the asOf date; verify live numbers before acting. DexCom typically trades at a premium valuation that reflects expectations for sustained double-digit growth, so its earnings multiple tends to be higher than the broader market; that premium leaves less room for error if growth slows or competition intensifies. Investors should weigh the CGM growth runway and coverage momentum against that elevated valuation and Abbott's competitive presence.

MDT. Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.

Headline figures (approximate, Jul 2026): DXCM shows revenue (q1 2026) ~$1.19 billion, up about 15% year over year, net income (q1 2026) ~$199.5 million, or about $0.51 per share, 2026 revenue guidance $5.16 to $5.25 billion (reiterated), coverage expansion targeting more than 7 million covered type 2 non-insulin lives by year end; MDT shows revenue (ttm) ~$33 billion, operating margin ~20% (non-GAAP higher; GAAP affected by amortization), net income (ttm) ~$4.5 billion, eps (ttm) ~$3.50 GAAP; non-GAAP higher.

DXCM and MDT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DXCM and MDT exposure against your real portfolio. It is not an investment adviser.